VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,289 | -74.5% | 1,163 | -75.1% | 0.00% | -75.0% |
| Q2 2023 | $232,870 | +247634.0% | 4,663 | +86.7% | 0.01% | +166.7% |
| Q1 2023 | $94 | +168.6% | 2,497 | +236.5% | 0.00% | +200.0% |
| Q4 2022 | $35 | -100.0% | 742 | -90.7% | 0.00% | -66.7% |
| Q3 2022 | $191,000 | +4.4% | 7,942 | -5.4% | 0.00% | -25.0% |
| Q2 2022 | $183,000 | +695.7% | 8,395 | +757.5% | 0.00% | – |
| Q1 2022 | $23,000 | -39.5% | 979 | -39.8% | 0.00% | -100.0% |
| Q4 2021 | $38,000 | -5.0% | 1,627 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $40,000 | -27.3% | 1,570 | -36.2% | 0.00% | 0.0% |
| Q2 2021 | $55,000 | -3.5% | 2,460 | -14.7% | 0.00% | 0.0% |
| Q1 2021 | $57,000 | 0.0% | 2,884 | +34.0% | 0.00% | -50.0% |
| Q4 2020 | $57,000 | -58.1% | 2,152 | -22.1% | 0.00% | 0.0% |
| Q3 2020 | $136,000 | – | 2,761 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |